Share Prices & Company Research

Market News

03 Feb 2021 | 07:01

GSK, Curevac in venture to develop vaccine for Covid-19 variants

(Sharecast News) - GlaxoSmithKline and CureVac on Wednesday announced a new €150m collaboration to develop a vaccine to combat emerging variants of Covid-19. GSK added that it would also support the manufacture of up to 100m doses of CureVac's first generation Covid-19 vaccine candidate CVnCoV in 2021.

The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval, GSK said.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.